Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Published byPhebe Newton Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2."— Presentation transcript:

1 Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2 divided into ER-positive and -negative groups. From: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Ann Oncol. 2014;25(8): doi: /annonc/mdu112 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 2. Interactions between stromal tumor-infiltrating lymphocytes (TILs) and trastuzumab benefit in HER2+ disease. (A) Forest plots indicate the prognostic effect of each 10% increment in TILs according to trastuzumab treatment arm. Hazard ratios are derived from Cox regression models stratified by chemotherapy, together with 95% confidence interval (CI) and interaction P-value for distant disease-free survival. (B) For illustration, Kaplan–Meier curves comparing trastuzumab versus no trastuzumab for two groups of patients with <50% and >50% levels of stromal TILs (LPBC, lymphocyte predominant breast cancer) at diagnosis are presented (log-rank P values are shown). From: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Ann Oncol. 2014;25(8): doi: /annonc/mdu112 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2."

Similar presentations

Fig. 1. Flow diagram of study participants and outcomes.

Fig. 1. Flow diagram of study participants and outcomes.
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.
Fig. 7. Estimated damage ratio (eqn 3) of Abies mariesii along an altitude. The lines indicate 5, 10, 20 and 40 cm of DBH, as shown. Regression lines are.

Fig. 7. Estimated damage ratio (eqn 3) of Abies mariesii along an altitude. The lines indicate 5, 10, 20 and 40 cm of DBH, as shown. Regression lines are.
Figure 1 Representative longitudinal strain analysis in an apical two-chamber view. The view is presented in the left panel and the longitudinal strain.

Figure 1 Representative longitudinal strain analysis in an apical two-chamber view. The view is presented in the left panel and the longitudinal strain.
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.
From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj
Figure 1 (A) Chest computed tomography scans of the patient

Figure 1 (A) Chest computed tomography scans of the patient
Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. (A) Sézary syndrome patient before treatment
Figure 2. Kaplan–Meier survival analysis in patients

Figure 2. Kaplan–Meier survival analysis in patients
Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

Similar presentations

Ads by Google